Small CDMO
Market Cap
₹16,328 ₹16,328 Cr.
P/E
46.37
PEG = P/E ÷ 5yr Forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.46
Div Yield (%)
Div Yield (%)
0.49
Individual < 2 lac
Individual < 2 lac
10.73 %
Institutions
Institutions
28.27 %
Market cap
Market cap
16,328 Cr
No. of Shareholders
No. of Shareholders
82,703
OPM (%)
OPM (%)
14.15 %
PE
PE
46.37
Prom Holding
Prom Holding
47.68 %
ROCE (%)
ROCE (%)
6.96
ROE (%)
ROE (%)
5.62
Sales
Sales
8,608 Cr
  • Jubilant Pharmova
  • Alembic Pharma
  • Astrazeneca Pharma
  • TJI Pharma - API & CRAMS
Last updated on 11 Sep 2026
  • Jubilant Pharmova makes radiopharma with Ruby-Fill cardiac PET and SPECT supply, sterile injectable CDMO including ophthalmics, CRDMO with discovery and API, allergy extracts and solid-dosage generics.
  • Radiopharma is the largest profit base at ~46%. CDMO and Discovery are the growth vectors. SPECT shortages, API and Generics drag earnings.
  • It runs 45 US radiopharmacies and sterile fill-finish at Spokane and Montreal. Per management, its integrated SPECT plus PET network is a moat.
  • It is building Spokane Lines 3-4, Montreal Line 5 and six PET sites. Management guides ~₹1,660Cr capex for FY27. The shift is toward complex biologics.
  • Growth is funded ahead of earnings. Net debt/EBITDA rose to 1.8x in Mar-2026.
  • It is in mid-recovery. Near-term profit depends on Montreal and SPECT fixes. Management guides 17–18% EBITDA margin for H2 FY27, reaffirmed in August.
  • 81% of revenue is linked to the US. 78% of US-sold goods originate in the US, with the rest from Canada and India.
  • Montreal remediation FY27 quarters
    SPECT batches restart with first release in Q2 and all products in H2.
  • H2 margin recovery H2 FY27
    H2 EBITDA returns toward guided 17–18% as Montreal remediation completes and pre-commissioning costs ease.
  • Spokane Line 3 late FY27
    First commercial revenue starts after FDA product clearance and VAI inspection outcome.
  • Six PET sites FY28 (was first 3 FY27/balance FY28)
    New PET capacity comes online under the USD 60Mn programme.
  • GST demands No timeline
    Contested demands of ₹105.5Cr plus interest and ₹87.31Cr are resolved or crystallise.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
786
52W Range
High
1185
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

1 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

62 %
(as of Mar 18)
Acetic Anhydride - Domestic Market Share
0.06 %
(as of Jul 22)
Anti - Diabetes - Market Share
0.06 %
(as of Jul 22)
Cardiovascular - Market Share
0.01 %
(as of Feb 21)
Neurological - Market Share
0.02 %
(as of Jul 22)
Pharmaceutical Sector - Market Share
0.03 %
(as of Jul 22)
Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up - Contract Research

Location Wise Break-Up - Pharmaceuticals

Location Wise Break-Up

Operating Profit Break-Up

Capex

Asset Break-Up

Operational Metrics

    Select a Metric
    • Australia DMF fillings (.)
    • Number of ANDA's Filed in Europe
    • Number of ANDA's Approved in Europe
    • Number of ANDA's Filed in Canada
    • Number of ANDA's Approved by Canada
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Approved By USFDA (.)
    • US DMF Filings (.)
    • Canada DMF fillings (.)
    • Japan DMF Filings (.)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Suppliers

    • Aegis Logistics Ltd.
    • Time Technoplast Ltd.
    • Balaji Amines Ltd.
    • GMM Pfaudler Ltd.
    • Deep Energy Resources Ltd. - (Amalgamated)

    FAQs on Jubilant Pharmova Ltd. Business

    Jubilant Pharmova Limited operates globally in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Novel Drugs with a strong manufacturing presence in Radiopharmaceutical products for regulated markets.

    Jubilant Pharmova major competitors are Alembic Pharma, Astrazeneca Pharma, Marksans Pharma, Natco Pharma, Eris Lifesciences, Pfizer, Caplin Point Labs..
    Market Cap of Jubilant Pharmova is ₹16,119 Crs.
    While the median market cap of its peers are ₹17,002 Crs.

    Jubilant Pharmova seems to be less financially stable compared to its competitors.
    Altman Z score of Jubilant Pharmova is 2.68 and is ranked 8 out of its 8 competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Feb May Jul Oct Mar Jun Sep Dec Mar Jun Sep Dec Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Jun Sep Dec Jun Sep Jun Sep Sep Dec
    Investor Presentation Feb May Aug May Jul Aug Oct Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Sep Dec Mar Jun Mar Jun Sep Dec
    Conference Call May Mar Jun Sep Dec Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Sep Dec Jun Sep Dec
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material